GlassScriptPhysician profile
Maci Woodson
NPI 1174385108
$2,900.59
in general payments reported to CMS, 2019-2025
22 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $35.34 · 2024: $1,665 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.59 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $520.58 | 2023-2025 | |
| Strata Skin Sciences, INC. | $417.77 | 2024-2025 | Xtrac |
| Galderma Laboratories, L.P. | $354.86 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $305.55 | 2025 | |
| Janssen Biotech, INC. | $236.38 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $204.07 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $148.46 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $129.84 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $102.72 | 2024-2025 | |
| Incyte Corporation | $73.49 | 2024-2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $62.31 | 2024-2025 | Ycanth |
| Sun Pharmaceutical Industries INC. | $47.40 | 2024-2025 | |
| Biofrontera INC. | $43.63 | 2025 | |
| Amgen INC. | $37.63 | 2024-2025 | Otezla |
| Ucb, INC. | $37.45 | 2025 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $36.37 | 2025 | Libtayo |
| Botanix Sb INC | $35.15 | 2025 | Sofdra |
| Leo Pharma INC. | $30.48 | 2024 | Adbry |
| Merz North America, INC. | $21.94 | 2025 | |
| Pfizer INC. | $18.73 | 2025 | |
| Organogenesis INC. | $18.14 | 2025 | Apligraf |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.64 | 2025 | Siliq, Jublia, Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maci Woodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.